Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Secondary Efficacy Outcomes from Two Pivotal Phase 3 Trials

Linda Stein Gold; Andrew Blauvelt; April Armstrong; Seemal R. Desai; Howard Sofen; Lawrence J. Green; Stephen K. Tyring; Laura K. Ferris; Philip M. Brown; David S. Rubenstein; Stephen C. Piscitelli; Anna M. Tallman; Leon Kircik

doi:10.25251/skin.6.supp.6

Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Secondary Efficacy Outcomes from Two Pivotal Phase 3 Trials

Linda Stein Gold, Andrew Blauvelt, April Armstrong, Seemal R. Desai, Howard Sofen, Lawrence J. Green, Stephen K. Tyring, Laura K. Ferris, Philip M. Brown, David S. Rubenstein, Stephen C. Piscitelli, Anna M. Tallman, Leon Kircik

Research output: Contribution to journal › Comment/debate

Original language	English
Journal	SKIN: Journal of Cutaneous Medicine
Volume	6
Issue number	2
DOIs	https://doi.org/10.25251/skin.6.supp.6
State	Published - 4 Mar 2022

Access to Document

10.25251/skin.6.supp.6

Cite this

Gold, L. S., Blauvelt, A., Armstrong, A., Desai, S. R., Sofen, H., Green, L. J., Tyring, S. K., Ferris, L. K., Brown, P. M., Rubenstein, D. S., Piscitelli, S. C., Tallman, A. M., & Kircik, L. (2022). Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Secondary Efficacy Outcomes from Two Pivotal Phase 3 Trials. SKIN: Journal of Cutaneous Medicine, 6(2). https://doi.org/10.25251/skin.6.supp.6

@article{59acd5b5a79d4a32b8371e768ee627b1,

title = "Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Secondary Efficacy Outcomes from Two Pivotal Phase 3 Trials",

author = "Gold, {Linda Stein} and Andrew Blauvelt and April Armstrong and Desai, {Seemal R.} and Howard Sofen and Green, {Lawrence J.} and Tyring, {Stephen K.} and Ferris, {Laura K.} and Brown, {Philip M.} and Rubenstein, {David S.} and Piscitelli, {Stephen C.} and Tallman, {Anna M.} and Leon Kircik",

note = "Funding Information: The authors thank the participating investigators, patients and their families, and colleagues involved in the conduct of the trials. L.S.G. has served as a consultant, and/or has received payment for the development of educational presentations, and/or has received grants from Arcutis, Amgen, Bristol-Myers Squibb, Dermavant Sciences, Inc., Eli Lilly, LEO Pharma, Ortho Dermatologic, and UCB Biopharma. A.B. has served as a scientific adviser and/ or clinical study investigator for AbbVie, Abcentra, Aligos, Almirall, Amgen, Arcutis, Arena, Aslan, Athenex, Boehringer Ingelheim, Bristol-Myers Squibb, Dermavant Sciences, Inc., Eli Lilly and Company, Evommune, Forte, Galderma, Incyte, Janssen, Landos, Leo, Novartis, Pfizer, Rapt, Regeneron, Sanofi Genzyme, Sun Pharma, and UCB Pharma. A.A. is a research investigator and/or scientific advisor to AbbVie, Bristol-Myers Squibb, Boehringer Ingelheim, EPI, Incyte, Leo, UCB, Janssen, Lilly, Novartis, Ortho Dermatologics, Sun, Dermavant Sciences Inc., Dermira, Sanofi, Regeneron, Pfizer, and Modmed. S.R.D. declares no financial relationships. H.S. has served as scientific adviser and/or clinical study investigator for AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Dermavant, Sciences Inc., Eli Lilly, Incyte, Janssen, LEO Pharma, Novartis, Pfizer, Sanofi-Genzyme, Sun Pharma, and UCB. L.J.G. is an investigator, speaker, or consultant for Amgen, AbbVie, Arcutis, Bristol-Myers Squibb, Dermavant, Lilly, MC-2, Orthoderm, SunPharma, and UCB. S.K.T. participated in studies sponsored by Dermavant, the manufacturer of tapinarof. L.K.F. is an investigator for AbbVie, Amgen, Arcutis, Bristol-Myers Squibb, Boehringer Ingelheim, Dermavant, Eli Lilly, Galderma, Janssen, Novartis, Regeneron and UCB, and a consultant for AbbVie, Arcutis, Bristol-Myers Squibb, Dermavant, Eli Lilly, Janssen, Pfizer, and Sun Pharma. P.M.B., D.S.R., S.C.P., and A.M.T. are employees of Dermavant Sciences Inc., with stock options. Editorial and medical writing support under the guidance of the authors was provided by ApotheCom, UK, and was funded by Dermavant Sciences, Inc. in accordance with Good Publication Practice (GPP3) guidelines (Ann Intern Med. 2015;163:461–464). Funding Information: The authors thank the participating investigators, patients and their families, and colleagues involved in the conduct of the trials. L.S.G. has served as a consultant, and/or has received payment for the development of educational presentations, and/or has received grants from Arcutis, Amgen, Bristol-Myers Squibb, Dermavant Sciences, Inc., Eli Lilly, LEO Pharma, Ortho Dermatologic, and UCB Biopharma. A.B. has served as a scientific adviser and/ or clinical study investigator for AbbVie, Abcentra, Aligos, Almirall, Amgen, Arcutis, Arena, Aslan, Athenex, Boehringer Ingelheim, Bristol-Myers Squibb, Dermavant Sciences, Inc., Eli Lilly and Company, Evommune, Forte, Galderma, Incyte, Janssen, Landos, Leo, Novartis, Pfizer, Rapt, Regeneron, Sanofi Genzyme, Sun Pharma, and UCB Pharma. A.A. is a research investigator and/or scientific advisor to AbbVie, Bristol-Myers Squibb, Boehringer Ingelheim, EPI, Incyte, Leo, UCB, Janssen, Lilly, Novartis, Ortho Dermatologics, Sun, Dermavant Sciences Inc., Dermira, Sanofi, Regeneron, Pfizer, and Modmed. S.R.D. declares no financial relationships. H.S. has served as scientific adviser and/or clinical study investigator for AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Dermavant, Sciences Inc., Eli Lilly, Incyte, Janssen, LEO Pharma, Novartis, Pfizer, Sanofi-Genzyme, Sun Pharma, and UCB. L.J.G. is an investigator, speaker, or consultant for Amgen, AbbVie, Arcutis, Bristol-Myers Squibb, Dermavant, Lilly, MC-2, Orthoderm, SunPharma, and UCB. S.K.T. participated in studies sponsored by Dermavant, the manufacturer of tapinarof. L.K.F. is an investigator for AbbVie, Amgen, Arcutis, Bristol-Myers Squibb, Boehringer Ingelheim, Dermavant, Eli Lilly, Galderma, Janssen, Novartis, Regeneron and UCB, and a consultant for AbbVie, Arcutis, Bristol-Myers Squibb, Dermavant, Eli Lilly, Janssen, Pfizer, and Sun Pharma. P.M.B., D.S.R., S.C.P., and A.M.T. are employees of Dermavant Sciences Inc., with stock options. Editorial and medical writing support under the guidance of the authors was provided by ApotheCom, UK, and was funded by Dermavant Sciences, Inc. in accordance with Good Publication Practice (GPP3) guidelines (Ann Intern Med. 2015;163:461–464). Contact Dr Linda Stein Gold at [email protected] with questions or comments.",

year = "2022",

month = mar,

day = "4",

doi = "10.25251/skin.6.supp.6",

language = "English",

volume = "6",

journal = "SKIN: Journal of Cutaneous Medicine",

issn = "2574-1624",

publisher = "National Society for Cutaneous Medicine",

number = "2",

}

Gold, LS, Blauvelt, A, Armstrong, A, Desai, SR, Sofen, H, Green, LJ, Tyring, SK, Ferris, LK, Brown, PM, Rubenstein, DS, Piscitelli, SC, Tallman, AM & Kircik, L 2022, 'Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Secondary Efficacy Outcomes from Two Pivotal Phase 3 Trials', SKIN: Journal of Cutaneous Medicine, vol. 6, no. 2. https://doi.org/10.25251/skin.6.supp.6

TY - JOUR

T1 - Tapinarof Cream 1% Once Daily for Plaque Psoriasis

T2 - Secondary Efficacy Outcomes from Two Pivotal Phase 3 Trials

AU - Gold, Linda Stein

AU - Blauvelt, Andrew

AU - Armstrong, April

AU - Desai, Seemal R.

AU - Sofen, Howard

AU - Green, Lawrence J.

AU - Tyring, Stephen K.

AU - Ferris, Laura K.

AU - Brown, Philip M.

AU - Rubenstein, David S.

AU - Piscitelli, Stephen C.

AU - Tallman, Anna M.

AU - Kircik, Leon

N1 - Funding Information: The authors thank the participating investigators, patients and their families, and colleagues involved in the conduct of the trials. L.S.G. has served as a consultant, and/or has received payment for the development of educational presentations, and/or has received grants from Arcutis, Amgen, Bristol-Myers Squibb, Dermavant Sciences, Inc., Eli Lilly, LEO Pharma, Ortho Dermatologic, and UCB Biopharma. A.B. has served as a scientific adviser and/ or clinical study investigator for AbbVie, Abcentra, Aligos, Almirall, Amgen, Arcutis, Arena, Aslan, Athenex, Boehringer Ingelheim, Bristol-Myers Squibb, Dermavant Sciences, Inc., Eli Lilly and Company, Evommune, Forte, Galderma, Incyte, Janssen, Landos, Leo, Novartis, Pfizer, Rapt, Regeneron, Sanofi Genzyme, Sun Pharma, and UCB Pharma. A.A. is a research investigator and/or scientific advisor to AbbVie, Bristol-Myers Squibb, Boehringer Ingelheim, EPI, Incyte, Leo, UCB, Janssen, Lilly, Novartis, Ortho Dermatologics, Sun, Dermavant Sciences Inc., Dermira, Sanofi, Regeneron, Pfizer, and Modmed. S.R.D. declares no financial relationships. H.S. has served as scientific adviser and/or clinical study investigator for AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Dermavant, Sciences Inc., Eli Lilly, Incyte, Janssen, LEO Pharma, Novartis, Pfizer, Sanofi-Genzyme, Sun Pharma, and UCB. L.J.G. is an investigator, speaker, or consultant for Amgen, AbbVie, Arcutis, Bristol-Myers Squibb, Dermavant, Lilly, MC-2, Orthoderm, SunPharma, and UCB. S.K.T. participated in studies sponsored by Dermavant, the manufacturer of tapinarof. L.K.F. is an investigator for AbbVie, Amgen, Arcutis, Bristol-Myers Squibb, Boehringer Ingelheim, Dermavant, Eli Lilly, Galderma, Janssen, Novartis, Regeneron and UCB, and a consultant for AbbVie, Arcutis, Bristol-Myers Squibb, Dermavant, Eli Lilly, Janssen, Pfizer, and Sun Pharma. P.M.B., D.S.R., S.C.P., and A.M.T. are employees of Dermavant Sciences Inc., with stock options. Editorial and medical writing support under the guidance of the authors was provided by ApotheCom, UK, and was funded by Dermavant Sciences, Inc. in accordance with Good Publication Practice (GPP3) guidelines (Ann Intern Med. 2015;163:461–464). Funding Information: The authors thank the participating investigators, patients and their families, and colleagues involved in the conduct of the trials. L.S.G. has served as a consultant, and/or has received payment for the development of educational presentations, and/or has received grants from Arcutis, Amgen, Bristol-Myers Squibb, Dermavant Sciences, Inc., Eli Lilly, LEO Pharma, Ortho Dermatologic, and UCB Biopharma. A.B. has served as a scientific adviser and/ or clinical study investigator for AbbVie, Abcentra, Aligos, Almirall, Amgen, Arcutis, Arena, Aslan, Athenex, Boehringer Ingelheim, Bristol-Myers Squibb, Dermavant Sciences, Inc., Eli Lilly and Company, Evommune, Forte, Galderma, Incyte, Janssen, Landos, Leo, Novartis, Pfizer, Rapt, Regeneron, Sanofi Genzyme, Sun Pharma, and UCB Pharma. A.A. is a research investigator and/or scientific advisor to AbbVie, Bristol-Myers Squibb, Boehringer Ingelheim, EPI, Incyte, Leo, UCB, Janssen, Lilly, Novartis, Ortho Dermatologics, Sun, Dermavant Sciences Inc., Dermira, Sanofi, Regeneron, Pfizer, and Modmed. S.R.D. declares no financial relationships. H.S. has served as scientific adviser and/or clinical study investigator for AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Dermavant, Sciences Inc., Eli Lilly, Incyte, Janssen, LEO Pharma, Novartis, Pfizer, Sanofi-Genzyme, Sun Pharma, and UCB. L.J.G. is an investigator, speaker, or consultant for Amgen, AbbVie, Arcutis, Bristol-Myers Squibb, Dermavant, Lilly, MC-2, Orthoderm, SunPharma, and UCB. S.K.T. participated in studies sponsored by Dermavant, the manufacturer of tapinarof. L.K.F. is an investigator for AbbVie, Amgen, Arcutis, Bristol-Myers Squibb, Boehringer Ingelheim, Dermavant, Eli Lilly, Galderma, Janssen, Novartis, Regeneron and UCB, and a consultant for AbbVie, Arcutis, Bristol-Myers Squibb, Dermavant, Eli Lilly, Janssen, Pfizer, and Sun Pharma. P.M.B., D.S.R., S.C.P., and A.M.T. are employees of Dermavant Sciences Inc., with stock options. Editorial and medical writing support under the guidance of the authors was provided by ApotheCom, UK, and was funded by Dermavant Sciences, Inc. in accordance with Good Publication Practice (GPP3) guidelines (Ann Intern Med. 2015;163:461–464). Contact Dr Linda Stein Gold at [email protected] with questions or comments.

PY - 2022/3/4

Y1 - 2022/3/4

UR - http://www.scopus.com/inward/record.url?scp=85136406316&partnerID=8YFLogxK

U2 - 10.25251/skin.6.supp.6

DO - 10.25251/skin.6.supp.6

M3 - Comment/debate

AN - SCOPUS:85136406316

SN - 2574-1624

VL - 6

JO - SKIN: Journal of Cutaneous Medicine

JF - SKIN: Journal of Cutaneous Medicine

IS - 2

ER -